The European League Against Rheumatism (EULAR) recently updated its recommendations for the management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDS), developing 12 recommendations on the use of conventional synthetic DMARDs and targeted synthetic DMARDs.
In one key area, the updated guideline remains unchanged from previous versions. EULAR recommends that patients with RA be treated initially with methotrexate, calling it the “anchor drug in RA.” Do you agree with this recommendation?